Abstract: A labeling method according to an embodiment may include: receiving a consultation dataset sentence; classifying the consultation dataset sentence into morpheme units and extracting target data; searching whether the target data is included in each of a plurality of categories of a word dictionary; and labeling the consultation dataset sentence in the word dictionary based on a result of the searching.

Abstract: A training method according to an embodiment may include: performing transfer learning a first artificial neural network model based on a consultation dataset sentence; inputting depressive disorder-related expression data into the first artificial neural network model, labeling the depressive disorder-related expression data according to depressive disorder diagnosis criteria, and generating labeled depressive disorder-related expression data; and training a second artificial neural network model based on the labeled depressive disorder-related expression data so that a second artificial neural network model may output the depressive disorder diagnosis criteria corresponding to input data.

Abstract: Disclosed are a pharmaceutical composition and a beauty-purposed pharmaceutical composition for prevention or treatment of neuromuscular disease, the composition including a combination of Erigeron annuus flower-based essential oil and Botox. Erigeron annuus flower-based essential oil inhibits t-SNARE protein and v-SNARE protein expression in neurons to inhibit the formation of SNARE protein complexes. Erigeron annuus flower-based essential oil inhibits the regeneration of t-SNARE protein and v-SNARE protein degraded by Botox to inhibit neurotransmitter release. Accordingly, an efficacy duration of Botox may be extended. Thus, Erigeron annuus flower-based essential oil may be usefully used in combination with Botox as Botox adjuvant for the prevention and treatment of neuromuscular disease or for beauty.

Abstract: Disclosed are a pharmaceutical composition and a beauty-purposed pharmaceutical composition for prevention or treatment of neuromuscular disease, the composition including a combination of Erigeron annuus flower-based essential oil and Botox. Erigeron annuus flower-based essential oil inhibits t-SNARE protein and v-SNARE protein expression in neurons to inhibit the formation of SNARE protein complexes. Erigeron annuus flower-based essential oil inhibits the regeneration of t-SNARE protein and v-SNARE protein degraded by Botox to inhibit neurotransmitter release. Accordingly, an efficacy duration of Botox may be extended. Thus, Erigeron annuus flower-based essential oil may be usefully used in combination with Botox as Botox adjuvant for the prevention and treatment of neuromuscular disease or for beauty.